One approach is targeting one of the key elements of BAD pathophysiology: the lack of negative feedback inhibition on the bile acid synthesis from the small intestine
Key findings Hit a protein floor first roughly 80120 g/day for most adults, or ~1.5 g per kg lean mass when you know it with shakes and mechanical eating when solid food fails
Published clinical trial data from Eli Lillys investigational Retatrutide program do not validate or authorize human use of this independently manufactured research product, which is designated exclusively for in vitro laboratory research
Markers of insulin sensitivity improved, fasting glucose trended lower, and A1C remained stable or decreased despite no pre-existing elevation
Highmarks approach is outlined below Please encourage your clients to complete Highmarks direct request for information
Mechanisms reported in the literature include: GLP-1 receptor activation Stimulates glucose-dependent insulin release Supports appetite regulation and satiety signaling Slows gastric emptying GIP receptor activation Augments insulin secretion Associated with -cell support and improved nutrient handling Glucagon receptor activation Linked to increased energy expenditure Promotes hepatic lipid mobilization and oxidation Clinical Research Evidence In a published Phase 2 randomized trial, retatrutide produced dose-dependent reductions in body weight, with the highest dose associated with up to approximately 24% mean body-weight reduction at 48 weeks , alongside improvements in cardiometabolic markers
&srotate=0)
